SecBot SecBot

NTLA

Intellia Therapeutics, Inc.
Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. DE· CIK 0001652130 Biotech & Drug DiscoveryGenomics & Gene Editing
$11.24 +0.03 (+0.27%)
Oct 26 4:00 PM ET · prev $11.21
Market cap
$1.6B
Small cap
Consensus
Buy
58% Buy or better · 24 analysts
Median target
$16.00
+42% · range $8.00–61.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.79
1 year
−24.0%
from $14.79 · Oct 27
30 days
−1.6%
from $11.42
52-week range
$8.04–17.84
−37% from high · low Nov 20
Avg volume 20D
5.63M
shares / day
Short interest
45.11M
≈32.2% of shares · −3.4%
Days to cover
9.5
at average volume
Insider net
-$554.8K
0 buyers · 5 sellers · 12 mo
New fund stakes
3
Q2 2026 13F · 0 exits
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Intellia Therapeutics announced FDA acceptance of its Biologics License Application (BLA) for lonvoguran…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $554.8K.

  • InstitutionsBULLISH

    Q2 2026: 51 added (3 new), 14 trimmed or exited. Largest new: Ra Capital Management, $76.6M, Renaissance Technologies $23.7M.

  • AnalystsBULLISH

    14 of 24 rate it Buy or better. Median target $16.00 (+42%).

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.780 → −$0.786 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −3.4% to 45.11M shares. 9.5 days to cover, ≈32.2% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$116.0M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD15,409,023$260.7M
STATE STREET CORPADD9,234,987$156.3M
FMR LLCDOUBLED4,773,034$80.8M
RA CAPITAL MANAGEMENT, L.P.NEW4,526,926$76.6M
GEODE CAPITAL MANAGEMENT, LLCADD3,631,061$61.4M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED3,280,760$55.5M
Sumitomo Mitsui Trust Group, Inc.ADD2,897,529$49.0M
GOLDMAN SACHS GROUP INCADD2,264,471$38.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

24 analysts
Buy 58% rate it Buy or better
Strong Buy4Buy10Hold7Sell2Strong Sell1
12-month targets · 18 analysts

Price is inside the target range. Median implies +42%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 6, 2026Barclays
INITIATE
INITIATEUnderweight
Sep 9, 2026Citizens
REITERATE
REITERATEMarket Outperform
Sep 9, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Sep 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 25, 2026Citizens
REITERATE
REITERATEMarket Outperform
Aug 7, 2026Evercore ISI Group
UPGRADE
UPGRADEOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$554.8K
sold · 5 insiders
DateInsiderTypeValue
Oct 2, 2026
Dube Michael P
VP, Chief Accounting Officer
SELL$23.2K
Aug 21, 2026
LEONARD JOHN M
President and CEO
SELL$36.2K
Aug 20, 2026
LEONARD JOHN M
President and CEO
SELL$250.6K
Jul 22, 2026
Dulac Edward J III
EVP, Chief Financial Officer
SELL$91.2K
Jul 2, 2026
Dulac Edward J III
EVP, Chief Financial Officer
SELL$84.2K
Jul 1, 2026
Dube Michael P
VP, Chief Accounting Officer
SELL$44.3K
Jun 9, 2026
Verwiel Frank
Director
AWARD13,300 sh
Jun 9, 2026
GOODMAN JESSE
Director
AWARD9,200 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.79
EPS estimate, this quarter
−1%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.79-$0.89–-$0.71+0.4%$9.8M
Next Q-$0.75-$0.91–-$0.41+1.3%$17.1M
Current FY🔒 Fresh data, subscribers only
Next FY-$2.56-$3.62–$0.97+1.3%$126.3M
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent posts
r/stocks Bullish 23d ago
Intellia Therapeutics ($NTLA): Bull case ahead of the 2027 FDA decision
1 upvotes · 0 comments
r/stocks Bullish 24d ago
Intellia Therapeutics to the MOOOONN x100
1 upvotes · 0 comments
r/wallstreetbets Bullish 24d ago
Why Intellia Therapeutics could become the next 10,000% bagger ($10k -> $1 million)
1 upvotes · 0 comments
Recent comments
r/thetagang Neutral 2d ago
Hey there. Thanks for the comments. With regards to the October slowdown it is a combination of volatility slowing down, the consistency of the portfolio, as well as a small change in options management. We know about the volatility, so the consistency has some factors; the first is the heavy concentration in HOOD and CRWD. I have 4 covered calls that are all blown in CRWD. It is up 118.06% YTD. The calls are in the $142.5 - $147.5 range, which means that the unrealized loss on them is $10k
All social signals and their track records

Short side

FINRA· Sep 30, 2026
45,110,513
shares short
-3.4%
vs prior settlement
9.5
days to cover
≈32.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 Press
Intellia Therapeutics granted inducement stock awards to eight new employees under its 2024 Inducement Plan. This is a…
Impact 2/10
Oct 2, 2026 Activist
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le
Oct 2, 2026 Insider
Dube Michael P sold 1,864 shares
VP, Chief Accounting Officer @ $12.43 ($23.2K)
Sep 8, 2026 SEC
Intellia Therapeutics announced FDA acceptance of its Biologics License Application (BLA) for lonvoguran ziclumeran…
8-K — Impact 7/10
Aug 21, 2026 Insider
LEONARD JOHN M sold 2,785 shares
President and CEO @ $13.00 ($36.2K)
Aug 20, 2026 Insider
LEONARD JOHN M sold 19,890 shares
President and CEO @ $12.60 ($250.6K)
Aug 6, 2026 SEC
Intellia Therapeutics reported Q2 2026 results with a net loss of $106.6M (-$0.80 EPS, -2.6% miss vs consensus) and…
8-K — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
15,409,023 shares ($260.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
NTLA Q3 2026 Earnings Scheduled — 2026-11-05
Mar 10, 2027
FDA decision date
PDUFA: NTLA — Lonvo-z in Hereditary Angioedema (HAE) — 2027-03-10
FDA target action date 2027-03-10 for NTLA (Intellia Therapeutics, Inc.). Drug: Lonvo-z. Indication: Hereditary Angioedema (HAE). PDUFA target…
Recent
Oct 2, 2026
Activist
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on…
Sep 4, 2026
Press release
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on…
Aug 6, 2026
Earnings
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on…
Aug 6, 2026
Earnings date
NTLA Q2 2026 Earnings Scheduled — 2026-08-06
Jul 30, 2026
Earnings date
NTLA Q2 2026 Earnings Scheduled — 2026-07-30

SecBot reports

9 filings · 6 press releases · 3 bullish · 0 bearish · 3 mixed · 3 neutral
All NTLA filing & press-release reports (15)